Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Dec 13:3:67.
doi: 10.3389/fmed.2016.00067. eCollection 2016.

Focus on Nivolumab in NSCLC

Diego L Cortinovis  1 , Stefania Canova  1 , Marida Abbate  1 , Francesca Colonese  1 , Paolo Bidoli  1
Affiliations
Review

Focus on Nivolumab in NSCLC

Diego L Cortinovis et al. Front Med (Lausanne). .

Abstract

Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues. The main doubts regarding the optimal selection of the patient are the role of this drug in first line of treatment, the individualization of the correct methodology of radiologic assessment and efficacy analysis, the best management of immune-mediated adverse events, and how to overcome the immunoresistance. The aim of this review is to analyze literature data on nivolumab in lung cancer with a focus on critical aspects related to the drug in terms of safety, the use in clinical practice, and possible placement in the treatment algorithm.

Keywords: NSCLC; PD-1; PDL1; checkpoint inhibitors; immunotherapy; nivolumab.

PubMed Disclaimer

References

    1. Morales-Cardenas A, Pérez-Madrid C, Arias A, Ojeda P, Mahecha MP, Rojas-Villarraga A, et al. Pulmonary involvement in systemic sclerosis. Autoimmun Rev (2016) 15(11):1094–108.10.1016/j.autrev.2016.07.025 - DOI - PubMed
    1. Blessing K, McLaren KM. Histological regression in primary cutaneous melanoma: recognition, prevalence and significance. Histopathology (1992) 20:315–22.10.1111/j.1365-2559.1992.tb00988.x - DOI - PubMed
    1. Gladwish A, Clarke K, Bezjak A. Spontaneous regression in advanced non-small cell lung cancer. BMJ Case Rep (2010).10.1136/bcr.07.2010.3147 - DOI - PMC - PubMed
    1. Ehrlich P. Ueber den jetzigen stand der Karzinomforschung. Ned Tijdschr Geneeskd (1909) 5:273–90.
    1. Old LJ, Boyse EA. Immunology of experimental tumors. Annu Rev Med (1964) 15:167–86.10.1146/annurev.me.15.020164.001123 - DOI - PubMed